Top

Open Access 17-04-2024 | Vagus Nerve Stimulation | Invited review article

Targeting inflammation in perivascular cells and neuroimmune interactions for treating kidney disease

Author: Shinji Tanaka

Published in: Clinical and Experimental Nephrology

Abstract

Inflammation plays a crucial role in the pathophysiology of various kidney diseases. Kidney perivascular cells (pericytes/fibroblasts) are responsible for producing proinflammatory molecules, promoting immune cell infiltration, and enhancing inflammation. Vascular adhesion protein-1, expressed in kidney perivascular cells, is an ectoenzyme that catalyzes the oxidative deamination of primary amines with the production of hydrogen peroxide in the extracellular space. Our study demonstrated that blocking this enzyme suppressed hydrogen peroxide production and neutrophil infiltration, thereby reducing renal ischemia–reperfusion injury. Sphingosine 1-phosphate (S1P) signaling was also observed to play an essential role in the regulation of perivascular inflammation. S1P, which is produced in kidney perivascular cells, is transported into the extracellular space via spinster homolog 2, and then binds to S1P receptor-1 expressed in perivascular cells. Upon injury, inflammatory signaling in perivascular cells is enhanced by this pathway, thereby promoting immune cell infiltration and subsequent fibrosis. Furthermore, inhibition of S1P transport by spinster homolog 2 reduces kidney fibrosis. Hypoxia-inducible factor-prolyl hydroxylase inhibitors can restore the capacity for erythropoietin production in kidney perivascular cells. Animal data suggested that these drugs could also alleviate kidney and lipid inflammation although the precise mechanism is still unknown. Neuroimmune interactions have been attracting significant attention due to their potential to benefit patients with inflammatory diseases. Vagus nerve stimulation is one of the most promising strategies for harnessing neuroimmune interactions and attenuating inflammation associated with various diseases, including kidney disease. Using cutting-edge tools, the vagal afferents–C1 neurons–sympathetic nervous system–splenic nerve–spleen–kidney axis responsible for kidney protection induced by vagus nerve stimulation was identified in our study. Further research is required to decipher other crucial systems that control kidney inflammation and to determine whether these novel strategies can be applied to patients with kidney disease.

Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet (London, England). 2019;394(10212):1949–64. https://doi.org/10.1016/S0140-6736(19)32563-2.CrossRefPubMed

Singbartl K, Ley K. Leukocyte recruitment and acute renal failure. J Mol Med (Berl). 2004;82(2):91–101. https://doi.org/10.1007/s00109-003-0498-8.CrossRefPubMed

Levey AS, James MT. Acute kidney injury. Ann Int Med. 2017;167(9):ITC66-ITC80. https://doi.org/10.7326/AITC201711070.

Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58–66. https://doi.org/10.1056/NEJMra1214243.CrossRefPubMedPubMedCentral

Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442–8. https://doi.org/10.1038/ki.2011.379.CrossRefPubMed

Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet (London, England). 2017;389(10075):1238–52. https://doi.org/10.1016/S0140-6736(16)32064-5.CrossRefPubMed

Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kottgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet (London, England). 2013;382(9887):158–69. https://doi.org/10.1016/S0140-6736(13)60439-0.CrossRefPubMed

Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–63. https://doi.org/10.1001/archinte.164.6.659.CrossRefPubMed

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305. https://doi.org/10.1056/NEJMoa041031.CrossRefPubMed

10.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMed

11.

Tanaka S, Sugiura Y, Saito H, Sugahara M, Higashijima Y, Yamaguchi J, et al. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int. 2018;94(5):912–25. https://doi.org/10.1016/j.kint.2018.04.025.CrossRefPubMed

12.

Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol. 2010;30(3):268–77. https://doi.org/10.1016/j.semnephrol.2010.03.005.CrossRefPubMedPubMedCentral

13.

Nemoto T, Burne MJ, Daniels F, O’Donnell MP, Crosson J, Berens K, et al. Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int. 2001;60(6):2205–14. https://doi.org/10.1046/j.1523-1755.2001.00054.x.CrossRefPubMed

14.

Rabb H, Mendiola CC, Saba SR, Dietz JR, Smith CW, Bonventre JV, et al. Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury. Biochem Biophys Res Commun. 1995;211(1):67–73. https://doi.org/10.1006/bbrc.1995.1779.CrossRefPubMed

15.

Salmela K, Wramner L, Ekberg H, Hauser I, Bentdal O, Lins LE, et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation. 1999;67(5):729–36. https://doi.org/10.1097/00007890-199903150-00015.CrossRefPubMed

16.

Kaitaniemi S, Grön K, Elovaara H, Salmi M, Jalkanen S, Elima K. Functional modulation of vascular adhesion protein-1 by a novel splice variant. PLoS ONE. 2013;8(1): e54151. https://doi.org/10.1371/journal.pone.0054151.CrossRefPubMedPubMedCentral

17.

Noonan T, Lukas S, Peet GW, Pelletier J, Panzenbeck M, Hanidu A, et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am J Clin Exp Immunol. 2013;2(2):172–85.PubMedPubMedCentral

18.

Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science. 1992;257(5075):1407–9. https://doi.org/10.1126/science.1529341.CrossRefPubMed

19.

Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med. 1993;178(6):2255–60. https://doi.org/10.1084/jem.178.6.2255.CrossRefPubMed

20.

Tanaka S, Tanaka T, Kawakami T, Takano H, Sugahara M, Saito H, et al. Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury. Kidney Int. 2017;92(1):154–64. https://doi.org/10.1016/j.kint.2017.01.014.CrossRefPubMed

21.

Weston CJ, Shepherd EL, Claridge LC, Rantakari P, Curbishley SM, Tomlinson JW, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest. 2015;125(2):501–20. https://doi.org/10.1172/JCI73722.CrossRefPubMed

22.

Niethammer P, Grabher C, Look AT, Mitchison TJ. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature. 2009;459(7249):996–9. https://doi.org/10.1038/nature08119.CrossRefPubMedPubMedCentral

23.

Yoo SK, Starnes TW, Deng Q, Huttenlocher A. Lyn is a redox sensor that mediates leukocyte wound attraction in vivo. Nature. 2011;480(7375):109–12. https://doi.org/10.1038/nature10632.CrossRefPubMedPubMedCentral

24.

Stark K, Eckart A, Haidari S, Tirniceriu A, Lorenz M, von Bruhl ML, et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs. Nat Immunol. 2013;14(1):41–51. https://doi.org/10.1038/ni.2477.CrossRefPubMed

25.

Leaf IA, Nakagawa S, Johnson BG, Cha JJ, Mittelsteadt K, Guckian KM, et al. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J Clin Invest. 2017;127(1):321–34. https://doi.org/10.1172/JCI87532.CrossRefPubMed

26.

Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15(3):144–58. https://doi.org/10.1038/s41581-019-0110-2.CrossRefPubMed

27.

Tanaka S, Zheng S, Kharel Y, Fritzemeier RG, Huang T, Foster D et al. Sphingosine 1-phosphate signaling in perivascular cells enhances inflammation and fibrosis in the kidney. Sci Transl Med. 2022;14(658):eabj2681. https://doi.org/10.1126/scitranslmed.abj2681

28.

Fritzemeier R, Foster D, Peralta A, Payette M, Kharel Y, Huang T, et al. Discovery of in vivo active Sphingosine-1-phosphate Transporter (Spns2) inhibitors. J Med Chem. 2022;65(11):7656–81. https://doi.org/10.1021/acs.jmedchem.1c02171.CrossRefPubMedPubMedCentral

29.

Wu Y, Li P, Goodwin AJ, Cook JA, Halushka PV, Zingarelli B, et al. miR-145a regulates pericyte dysfunction in a murine model of sepsis. J Infect Dis. 2020. https://doi.org/10.1093/infdis/jiaa184.CrossRefPubMedPubMedCentral

30.

Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13(11):1324–32. https://doi.org/10.1038/nm1663.CrossRefPubMed

31.

Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37(5):1043–55. https://doi.org/10.1053/jhep.2003.50182.CrossRefPubMed

32.

Kaneko K, Sato Y, Uchino E, Toriu N, Shigeta M, Kiyonari H, et al. Lineage tracing analysis defines erythropoietin-producing cells as a distinct subpopulation of resident fibroblasts with unique behaviors. Kidney Int. 2022;102(2):280–92. https://doi.org/10.1016/j.kint.2022.04.026.CrossRefPubMed

33.

Souma T, Yamazaki S, Moriguchi T, Suzuki N, Hirano I, Pan X, et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol. 2013;24(10):1599–616. https://doi.org/10.1681/ASN.2013010030.CrossRefPubMedPubMedCentral

34.

Asada N, Takase M, Nakamura J, Oguchi A, Asada M, Suzuki N, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011;121(10):3981–90. https://doi.org/10.1172/JCI57301.CrossRefPubMedPubMedCentral

35.

Chang YT, Yang CC, Pan SY, Chou YH, Chang FC, Lai CF, et al. DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys. J Clin Invest. 2016;126(2):721–31. https://doi.org/10.1172/JCI82819.CrossRefPubMedPubMedCentral

36.

Tanaka S, Tanaka T, Nangaku M. Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Renal Physiol. 2014;307(11):F1187–95. https://doi.org/10.1152/ajprenal.00425.2014.CrossRefPubMed

37.

Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17–25. https://doi.org/10.1681/ASN.2005070757.CrossRefPubMed

38.

Souma T, Nezu M, Nakano D, Yamazaki S, Hirano I, Sekine H, et al. Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol. 2016;27(2):428–38. https://doi.org/10.1681/ASN.2014121184.CrossRefPubMed

39.

Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG Jr. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2008;111(6):3236–44. https://doi.org/10.1182/blood-2007-10-117812.CrossRefPubMedPubMedCentral

40.

Sugahara M, Tanaka S, Tanaka T, Saito H, Ishimoto Y, Wakashima T, et al. Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice. J Am Soc Nephrol. 2020;31(3):560–77. https://doi.org/10.1681/ASN.2019060582.CrossRefPubMedPubMedCentral

41.

Locatelli F, Del Vecchio L. Hypoxia-inducible factor-prolyl hydroxyl domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs? J Am Soc Nephrol. 2022;33(11):1966–79. https://doi.org/10.1681/ASN.2022040413.CrossRefPubMedPubMedCentral

42.

Sugahara M, Tanaka T, Nangaku M. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. Pharmacol Ther. 2022;239: 108272. https://doi.org/10.1016/j.pharmthera.2022.108272.CrossRefPubMed

43.

Tanaka S, Portilla D, Okusa MD. Role of perivascular cells in kidney homeostasis, inflammation, repair and fibrosis. Nat Rev Nephrol. 2023;19(11):721–32. https://doi.org/10.1038/s41581-023-00752-7.CrossRefPubMed

44.

Tanaka S, Okusa MD. AKI and the neuroimmune axis. Semin Nephrol. 2019;39(1):85–95. https://doi.org/10.1016/j.semnephrol.2018.10.008.CrossRefPubMedPubMedCentral

45.

Tanaka S, Okusa MD. Crosstalk between the nervous system and the kidney. Kidney Int. 2020;97(3):466–76. https://doi.org/10.1016/j.kint.2019.10.032.CrossRefPubMed

46.

Watkins LR, Goehler LE, Relton JK, Tartaglia N, Silbert L, Martin D, et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett. 1995;183(1–2):27–31.CrossRefPubMed

47.

Bernik TR, Friedman SG, Ochani M, DiRaimo R, Ulloa L, Yang H, et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med. 2002;195(6):781–8.CrossRefPubMedPubMedCentral

48.

Hosoi T, Okuma Y, Matsuda T, Nomura Y. Novel pathway for LPS-induced afferent vagus nerve activation: possible role of nodose ganglion. Auton Neurosci. 2005;120(1–2):104–7. https://doi.org/10.1016/j.autneu.2004.11.012.CrossRefPubMed

49.

Rosas-Ballina M, Ochani M, Parrish WR, Ochani K, Harris YT, Huston JM, et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A. 2008;105(31):11008–13. https://doi.org/10.1073/pnas.0803237105.CrossRefPubMedPubMedCentral

50.

Rosas-Ballina M, Olofsson PS, Ochani M, Valdes-Ferrer SI, Levine YA, Reardon C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science. 2011;334(6052):98–101. https://doi.org/10.1126/science.1209985.CrossRefPubMedPubMedCentral

51.

Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384–8. https://doi.org/10.1038/nature01339.CrossRefPubMed

52.

Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007;117(2):289–96. https://doi.org/10.1172/JCI30555.CrossRefPubMedPubMedCentral

53.

Inoue T, Abe C, Sung SS, Moscalu S, Jankowski J, Huang L, et al. Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through α7nAChR+ splenocytes. J Clin Invest. 2016;126(5):1939–52. https://doi.org/10.1172/JCI83658.CrossRefPubMedPubMedCentral

54.

Hoeger S, Fontana J, Jarczyk J, Selhorst J, Waldherr R, Kramer BK, et al. Vagal stimulation in brain dead donor rats decreases chronic allograft nephropathy in recipients. Nephrol Dial Transplant. 2014;29(3):544–9. https://doi.org/10.1093/ndt/gft451.CrossRefPubMed

55.

Tanaka S, Abe C, Abbott SBG, Zheng S, Yamaoka Y, Lipsey JE et al. Vagus nerve stimulation activates two distinct neuroimmune circuits converging in the spleen to protect mice from kidney injury. Proc Natl Acad Sci U S A. 2021;118(12). https://doi.org/10.1073/pnas.2021758118.

56.

Abe C, Inoue T, Inglis MA, Viar KE, Huang L, Ye H, et al. C1 neurons mediate a stress-induced anti-inflammatory reflex in mice. Nat Neurosci. 2017;20(5):700–7. https://doi.org/10.1038/nn.4526.CrossRefPubMedPubMedCentral

57.

Goggins E, Mitani S, Tanaka S. Clinical perspectives on vagus nerve stimulation: present and future. Clin Sci (Lond). 2022;136(9):695–709. https://doi.org/10.1042/CS20210507.CrossRefPubMed

58.

Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016;113(29):8284–9. https://doi.org/10.1073/pnas.1605635113.CrossRefPubMedPubMedCentral

59.

Bonaz B, Sinniger V, Hoffmann D, Clarencon D, Mathieu N, Dantzer C, et al. Chronic vagus nerve stimulation in Crohn’s disease: a 6-month follow-up pilot study. Neurogastroenterol Motil. 2016;28(6):948–53. https://doi.org/10.1111/nmo.12792.CrossRefPubMed

Title: Targeting inflammation in perivascular cells and neuroimmune interactions for treating kidney disease
Author: Shinji Tanaka
Publication date: 17-04-2024
Publisher: Springer Nature Singapore
Keywords: Vagus Nerve Stimulation
Acute Kidney Injury
Acute Kidney Injury
Erythropoietin
Erythropoietin
Epoetin alfa
Chronic Kidney Disease
Published in: Clinical and Experimental Nephrology
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-024-02494-7

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage